Hong Kong Stock Exchange: E Fund Biomedical ETF (03186) will be available for trading and approved for inclusion in the list of designated securities for short selling starting March 23rd._News_inbFund.com - A one-stop service platform for overseas private equity fund inbfound.com

Hong Kong Stock Exchange: E Fund Biomedical ETF (03186) will be available for trading and approved for inclusion in the list of designated securities for short selling starting March 23rd.

2026-03-20 19:02

Zhitongcaijing

E Fund (Hong Kong) Solactive Biotech Select Index ETF (03186) has been approved by the Securities and Futures Commission of Hong Kong as a collective investment scheme and is expected to be traded on the Hong Kong Stock Exchange starting on Monday, March 23, 2026, and approved for inclusion as a designated security for short selling.

On March 20th, the Hong Kong Stock Exchange announced that the CSOP Solactive Biotech Innovation ETF (03186) has been approved by the Securities and Futures Commission as a collective investment scheme and is expected to begin trading on the Hong Kong Stock Exchange and be approved for short selling on March 23, 2026 (Monday).

Purvis: Inflation remains high, Fed's path unclear, investment strategy should not be disrupted by short-term fluctuations.

Fidelity International: If the situation in the Middle East continues to escalate, it may eliminate the possibility of the Federal Reserve cutting interest rates this year.

Customer Service

Add the WeCom